In a report published Tuesday, Barclays analysts downgraded the rating on Torchmark Corporation TMK from Overweight to Underweight, while reducing the price target from $60 to $53. The downgrade reflects low upside to the company's EPS expectations.
Torchmark stocks are currently overvalued and amongst the highest in the life insurance industry. There is little scope of appreciation in the near future.
"Torchmark has a strong franchise in middle-market life and supplemental health insurance in the U.S. However, we don't see much upside to EPS expectations over the next few years as a result of slowing premium growth and stable margins, and we view TMK as overvalued," the analysts stated.
The EPS estimate for FY2 has been reduced from $4.80 to $4.70.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in